STARTUP PROFILE

Neuracle

COUNTRY
China
FOUNDED
2011
CATEGORY
Brain-Computer Interface
Developing an implantable BCI system that decodes motor intent to support hand grasp restoration after cervical spinal cord injury.
Visit website →
Neurofounders Insights
$   Funding   -
Series C+
MODALITY
ECoG
FORM FACTOR
Implant
INTERFACE DEPTH
Minimally invasive
INDICATION
Paralysis/motor
TARGET USER
Patients
REGULATORY STAGE
Other approval
Neuracle sits in China’s clinical BCI segment, with NEO positioned around hand grasp restoration after cervical spinal cord injury. Its positioning is differentiated by a minimally invasive extradural interface and a narrow approved motor-restoration use case.
Mentioned in Market Notes
MOST RECENT COVERAGE
#
6
BCI Goes Commercial
21 July – 4 August 2026

Neuracle completed the world's first commercial implant of a modern brain-computer interface, placing its coin-sized NEO device in a patient who had lost hand function after a spinal cord injury a decade ago. Performed at Huashan Hospital in Shanghai, the procedure places the eight-electrode implant on the surface of the brain, where it reads motor intent and drives a robotic glove. NEO received Chinese regulatory approval in March, making it the first invasive BCI cleared for commercial use by any national regulator. Neuracle is actively exploring IPO opportunities.

Articles featuring
Neuracle